Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation

This publication has 25 references indexed in Scilit:

• Optimizing the Percutaneous Interventional Outcomes for Patients With Diabetes Mellitus
  Circulation, 1999
• Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors
  New England Journal of Medicine, 1999
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
  The Lancet, 1998
• Diabetes Mellitus, Glycoprotein IIb/IIIa Blockade, and Heparin
  Circulation, 1998
• Frequency of Adverse Clinical Events in the 12 Months Following Successful Intracoronary Stent Placement in Patients Treated With Aspirin and Ticlopidine (Without Warfarin)
  The American Journal of Cardiology, 1998
• Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization
  Journal of the American College of Cardiology, 1997
• Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
  New England Journal of Medicine, 1997
• Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study
  The Lancet, 1997
• Coronary Angioplasty and Intracoronary Thrombolysis Are of Limited Efficacy in Resolving Early Intracoronary Stent Thrombosis
  Journal of the American College of Cardiology, 1996
• Percutaneous Transluminal Coronary Angioplasty in 1985–1986 and 1977–1981
  New England Journal of Medicine, 1988